Antonino M.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
- Evaluation of Safety and Efficacy of Elacestrant in Combination Therapies for Patients with Metastatic Breast Cancer: A Phase 1b/2 Open-Label Umbrella Study
- Efficacy and Safety of Inavolisib plus Combination Therapy in Patients with Endocrine-Resistant HR+/HER2- Advanced Breast Cancer with Chromosome 8p Loss
- Phase 2 Trial of Fulvestrant and Combination Therapy for Second-Line HR+/HER2- Metastatic Breast Cancer Guided by Liquid Biopsy Algorithm
Data & Insights
Has run more than one trial at 206 of 526 partner sites.
Specializations
Advanced Breast Cancer Research
Focused on investigating novel therapeutic approaches for HER2-positive advanced solid tumors and metastatic breast cancer. Particular emphasis on evaluating treatment strategies for patients with hormone receptor-positive and HER2-negative variants.
- Advanced Stage Treatment Development
- HER2-Positive Tumor Management
- Endocrine-Sensitive Cancer Therapy
Explores combination therapies targeting specific molecular pathways including PIK3CA mutations.
Triple-Negative Breast Cancer
Specializes in developing treatments for triple-negative breast cancer, with particular focus on PD-L1 positive variants. Investigates innovative therapeutic combinations including immunotherapy approaches.
- First-line Therapy Development
- Post-surgical Treatment Strategies
- Immunotherapy Applications
Evaluates novel drug combinations incorporating targeted therapies and chemotherapy protocols.
Early-Stage Breast Cancer
Conducts research on early-stage breast cancer treatment, particularly focusing on chemotherapy-free approaches and targeted therapeutic strategies. Investigates biomarker-guided treatment selection.
- Neoadjuvant Treatment Protocols
- Recurrence Prevention Strategies
- Molecular-Guided Therapy
Studies innovative approaches using circulating tumor DNA monitoring for treatment guidance.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.